Antihypertensive Dosing During Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy

Journal of Cardiac Failure - Intersections 2026 Open access

Read full text
Authors: Nosheen Reza, Nadim Mahmud, Melissa A. Austin, Estherland Duqueney, Parth C. Patel, Ellen Boakye, Nicole Hornsby, Alejandro de Feria, Amy B. Marzolf, ANJALI TIKU OWENS
DOI: 10.1016/j.yjcafi.2025.12.010
Cited by: 0
References: 3

Abstract

Hypertension is common in individuals with hypertrophic cardiomyopathy (HCM); however, its optimal management has not been elucidated. Treatment with thiazide diuretics, angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), and dihydropyridine calcium channel blockers (DHP-CCBs), may worsen left ventricular outflow tract (LVOT) obstruction and symptoms.1 We previously demonstrated that blood pressure (BP) rises with LVOT gradient reduction in patients on mavacamten, a first-in-class cardiac myosin inhibitor (CMI), and remains elevated compared with baseline BP.

Fields of Study & Subjects

Cardiomyopathy and Myosin Studies Cardiac Imaging and Diagnostics Blood Pressure and Hypertension Studies

Publication details

Journal / source
Journal of Cardiac Failure - Intersections
Volume
2
Issue
2
Pages
176–178
Publication date
2 January 2026
Language
EN